Patent US4282315A successfully refreshed from Google Patents.
US4282315A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation of enriched whole virus radioligand
Assignee: Bayer Corp
•
Filing: 1979-09-13
•
Granted: 1981-08-04
•
Expires: 1999-09-13
Abstract
Abstract Obtaining a virus subpopulation, useful in qualitative and quantitative biological assay procedures, of enhanced sensitivity toward host cells for the virus by contacting a virus population with an inanimate substrate having moieties which mimic host cell receptor sites for cell binding protein of the virus and recovering as said subpopulation the portion of the initial virus population which complexes with the substrate.
Inventors
- 👤 Albert A. Luderer
- 👤 Hugh C. McDonald
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 09:29
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/70; C12N; C12N7/00; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; G01N33/58; G01N33/585; G01N33/586; C12N2760/00; C12N2760/00011; C12N2760/18011; C12N2760/18811; C12N2760/18851
Claims Analysis
Total Claims: 45
Claim 1
Independent Claim
74 words
A method for preparing a virus subpopulation characterized by significantly increased binding sensitivity toward host cells for the virus, which method comprises contacting a virus population with an inanimate substrate having moieties which mimic host cell receptor sites for cell binding protein of the virus, complexing at least a portion of the virus population with the substrate, removing non-complexed virus, dissociating the complex and recovering the complexed virus from the substrate as said subpopulation.
Claim 2
Independent Claim
74 words
A method for preparing a virus subpopulation characterized by significantly increased binding sensitivity toward host cells for the virus, which method comprises contacting a virus population with an inanimate substrate having moieties which mimic host cell receptor sites for cell binding protein of the virus, complexing at least a portion of the virus population with the substrate, removing non-complexed virus, dissociating the complex and recovering the complexed virus from the substrate as said subpopulation.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the substrate is immobilized.
Claim 4
Dependent Claim
19 words
The method of claim 2 wherein the virus and the substrate complex through sialic acid moieties of the substrate.
Claim 5
Dependent Claim
14 words
The method of claim 3 wherein the virus is an influenza virus or paramyxovirus.
Claim 6
Dependent Claim
11 words
The method of claim 4 wherein the virus is Sendai virus.
Claim 7
Dependent Claim
13 words
The method of claim 5 wherein the substrate is a protein or glycoprotein.
Claim 8
Dependent Claim
14 words
The method of claim 4 wherein the complex is dissociated by change in temperature.
Claim 9
Dependent Claim
14 words
The method of claim 5 wherein the complex is dissociated by change in temperature.
Claim 10
Dependent Claim
12 words
The biologically pure virus subpopulation prepared by the process of claim 1.
Claim 11
Dependent Claim
12 words
The biologically pure virus subpopulation prepared by the process of claim 4.
Claim 12
Dependent Claim
12 words
The biologically pure virus subpopulation prepared by the process of claim 6.
Claim 13
Independent Claim
71 words
A method for preparing a labeled virus subpopulation characterized by significantly increased binding sensitivity toward host cells for the virus, which method comprises contacting a virus population with an inanimate substrate having moieties which mimic host cell receptor sites for cell binding protein of the virus, complexing at least a portion of the virus population with the substrate, removing non-complexed virus from the substrate as a subpopulation and labeling the subpopulation.
Claim 14
Independent Claim
71 words
A method for preparing a labeled virus subpopulation characterized by significantly increased binding sensitivity toward host cells for the virus, which method comprises contacting a virus population with an inanimate substrate having moieties which mimic host cell receptor sites for cell binding protein of the virus, complexing at least a portion of the virus population with the substrate, removing non-complexed virus from the substrate as a subpopulation and labeling the subpopulation.
Claim 15
Dependent Claim
10 words
The method of claim 12 wherein the substrate is immobilized.
Claim 16
Dependent Claim
19 words
The method of claim 13 wherein the virus and the substrate complex through sialic acid moieties of the substrate.
Claim 17
Dependent Claim
14 words
The method of claim 14 wherein the virus is an influenza virus or paramyxovirus.
Claim 18
Dependent Claim
11 words
The method of claim 15 wherein the virus is Sendai virus.
Claim 19
Dependent Claim
13 words
The method of claim 16 wherein the substrate is a protein or glycoprotein.
Claim 20
Dependent Claim
14 words
The method of claim 15 wherein the complex is dissociated by change in temperature.
Claim 21
Dependent Claim
14 words
The method of claim 16 wherein the complex is dissociated by change in temperature.
Claim 22
Dependent Claim
13 words
The method of claim 12 wherein the label is radioactive, enzyme or fluorescent.
Claim 23
Dependent Claim
13 words
The method of claim 15 wherein the label is radioactive, enzyme or fluorescent.
Claim 24
Dependent Claim
13 words
The method of claim 16 wherein the label is radioactive, enzyme or fluorescent.
Claim 25
Dependent Claim
13 words
The biologically pure labeled virus subpopulation prepared by the process of claim 20.
Claim 26
Dependent Claim
13 words
The biologically pure labeled virus subpopulation prepared by the process of claim 21.
Claim 27
Dependent Claim
13 words
The biologically pure labeled virus subpopulation prepared by the process of claim 22.
Claim 28
Dependent Claim
33 words
In a biological complementary binding procedure wherein a whole cell virus is complexed with a complementary substrate, the improvement which comprises using the virus subpopulation of claim 9 as said whole cell virus.
Claim 29
Dependent Claim
17 words
The process of claim 26 wherein the substrate is cells, tissues, glycoproteins, body fluid or body exudate.
Claim 30
Independent Claim
102 words
A method for preparing a labeled virus subpopulation characterized by significantly increased binding sensitivity toward host cells for the virus, which method comprises contacting a virus population with cells, cell membranes, or cell parts or chemically modified cells, cell membranes or cell parts which have cell receptor sites for the cell binding protein of the virus, complexing at least a portion of the virus population with the cell, cell membrane or cell part or chemically modified derivative thereof, removing non-complexed virus, dissociating the complex and recovering the complexed virus from the cell or cell derivative as a subpopulation and labeling the subpopulation.
Claim 31
Independent Claim
102 words
A method for preparing a labeled virus subpopulation characterized by significantly increased binding sensitivity toward host cells for the virus, which method comprises contacting a virus population with cells, cell membranes, or cell parts or chemically modified cells, cell membranes or cell parts which have cell receptor sites for the cell binding protein of the virus, complexing at least a portion of the virus population with the cell, cell membrane or cell part or chemically modified derivative thereof, removing non-complexed virus, dissociating the complex and recovering the complexed virus from the cell or cell derivative as a subpopulation and labeling the subpopulation.
Claim 32
Dependent Claim
23 words
The method of claim 28 wherein the cell, cell membrane or cell part or chemical modification of the same is free or immobilized.
Claim 33
Dependent Claim
41 words
The method of claim 29 wherein the virus and the cell, cell membrane, or cell part or a chemically modified derivative of the same complex through sialic acid moieties of the cell, cell membrane, cell part or chemically modified derivative thereof.
Claim 34
Dependent Claim
14 words
The method of claim 30 wherein the virus is an influenza virus or paramyxovirus.
Claim 35
Dependent Claim
11 words
The method of claim 31 wherein the virus is Sendai virus.
Claim 36
Dependent Claim
14 words
The method of claim 31 wherein the complex is dissociated by change in temperature.
Claim 37
Dependent Claim
14 words
The method of claim 32 wherein the complex is dissociated by change in temperature.
Claim 38
Dependent Claim
46 words
In a qualitative or quantitive competitive binding assay process wherein a radioactive labeled, enzyme labeled or fluorescent labeled influenza virus or paramyxovirus is used, the improvement which comprises using the radioactive labeled, enzyme labeled or fluorescent labeled virus subpopulation of claim 23 as said labeled virus.
Claim 39
Dependent Claim
14 words
The process of claim 35 wherein the labeled virus subpopulation is radiolabeled Sendai virus.
Claim 40
Dependent Claim
18 words
The process of claim 36 wherein the labeled virus subpopulation is used as an antigen in a radioimmunoassay.
Claim 41
Dependent Claim
17 words
The process of claim 36 wherein the labeled virus subpopulation is used in an antibody binding study.
Claim 42
Dependent Claim
20 words
The process of claim 36 wherein the labeled virus subpopulation is used to quantitate sialic acid-containing protein in a radioimmunoassay.
Claim 43
Dependent Claim
20 words
The process of claim 36 wherein the labeled virus subpopulation is used to quantitate Sendai virus or Sendai virus protein.
Claim 44
Dependent Claim
36 words
The process of claim 36 wherein the labeled virus subpopulation is used as a radioligand to detect and/or quantitate cells, tissues, glycoproteins or body fluids or exudates which contain various sialic acid receptors, including acetylneuraminic acid.
Claim 45
Dependent Claim
21 words
The process of claim 36 wherein the labeled virus is used to differentiate between glycolylneuraminic acid-containing proteins and acetylneuraminic acid-containing proteins.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-08-03 | 1985-02-02 | 1985-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-08-03 | 1989-02-02 | 1989-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-08-03 | 1993-02-02 | 1993-08-04 | $7700.00 | Window Closed / Lapsed |